Systemic and Renal Pharmacokinetics of Adefovir and Tenofovir Upon Coadministration
- 1 August 2005
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 45 (8) , 935-940
- https://doi.org/10.1177/0091270005278949
Abstract
Adefovir and tenofovir are nucleotide analogs that undergo renal secretion by the human renal organic anion transporter. The pharmacokinetics of tenofovir and adefovir following the administration of tenofovir disoproxil fumarate and adefovir dipivoxil alone and together were determined in 24 healthy subjects in an 8‐day, open‐label, fixed‐sequence study. Subjects received oral doses of adefovir dipivoxil on days 1 and 8 and oral doses of tenofovir disoproxil fumarate on days 2 to 8. Pharmacokinetic sampling was performed on days 1, 7, and 8. The plasma pharmacokinetics of tenofovir and adefovir were unaltered upon coadministration. Furthermore, the renal clearances (CLrenal) of tenofovir and adefovir were unaffected by their coadministration. The plasma Cmax values of tenofovir and adefovir were 33‐fold and 340‐fold lower than their Km values for the human renal organic anion transporter. These results demonstrate that coadministration of tenofovir disoproxil fumarate and adefovir dipivoxil does not result in substantial changes to their individual pharmacokinetic profiles.Keywords
This publication has 15 references indexed in Scilit:
- An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individualsAIDS, 2003
- Human Immunodeficiency Virus (HIV) Type 1 Reverse Transcriptase Resistance Mutations in Hepatitis B Virus (HBV)-HIV-Coinfected Patients Treated for HBV Chronic Infection Once Daily with 10 Milligrams of Adefovir Dipivoxil Combined with LamivudineAntimicrobial Agents and Chemotherapy, 2002
- A drug-drug interaction study between adefovir dipivoxil and lamivudine, acetaminophen, ibuprofen and trimethoprim/sulfamethoxazoleJournal of Hepatology, 2002
- Adefovir dipivoxil safety and pharmacokinetics in subjects with hepatitis B virus infection and in healthy subjectsJournal of Hepatology, 2002
- Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected AdultsAntimicrobial Agents and Chemotherapy, 2001
- HUMAN RENAL ORGANIC ANION TRANSPORTER 1 (hOAT1) AND ITS ROLE IN THE NEPHROTOXICITY OF ANTIVIRAL NUCLEOTIDE ANALOGSNucleosides, Nucleotides and Nucleic Acids, 2001
- Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L‐FMAU, DAPD, penciclovir and lobucavirJournal of Viral Hepatitis, 2000
- Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patientsAntimicrobial Agents and Chemotherapy, 1995
- Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurineAntimicrobial Agents and Chemotherapy, 1993
- Association of hepatitis B surface antigen and core antibody with acquisition and manifestations of human immunodeficiency virus type 1 (HIV-1) infection.American Journal of Public Health, 1990